alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>


<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUN-30-1996
<PERIOD-START>                             JUL-01-1995
<PERIOD-END>                               SEP-30-1995
<CASH>                                       1,760,152
<SECURITIES>                                 9,582,972
<RECEIVABLES>                                9,251,929
<ALLOWANCES>                                   697,422
<INVENTORY>                                  5,136,917
<CURRENT-ASSETS>                            27,033,537
<PP&E>                                       6,623,080
<DEPRECIATION>                               2,079,126
<TOTAL-ASSETS>                              35,531,797
<CURRENT-LIABILITIES>                        4,183,123
<BONDS>                                      4,590,000
<COMMON>                                       439,197
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                  26,319,477
<TOTAL-LIABILITY-AND-EQUITY>                35,531,797
<SALES>                                     10,436,583
<TOTAL-REVENUES>                            10,436,583
<CGS>                                        6,484,185
<TOTAL-COSTS>                                8,994,716
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                               169,340
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              1,518,265
<INCOME-TAX>                                   523,802
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   994,463
<EPS-PRIMARY>                                4,455,893
<EPS-DILUTED>                                4,411,988
        



</TABLE>
EXHIBIT 22 - SUBSIDIARIES OF THE COMPANY

COMPANY                                   STATE OF INCORPORATION
--------------------------------------------------------------------------------
Daher America, Inc.                                   Delaware
Dacom Lines, Inc.                                     Texas
Golden Eagle International Forwarding, Inc.           Florida
Golden Eagle Customs Brokers, Inc.                    Florida
Bridgeport Shipping, Inc.                             Florida
World Trade Transport of Virginia, Inc.               Virginia
WTT Customs Brokers, Inc.                             Virginia
Columbia Shipping Group, Inc.                         Delaware
Columbia Shipping, Inc. (NY)                          New York
Columbia Shipping, Inc. (WEST)                        California
Columbia Shipping, Inc. (SFO)                         California
Columbia Shipping, Inc. (Chicago)                     Illinois
Freight Express International, Inc.                   New York
Hydroxyurea Use for 

Sickle Cell Disease

Hydroxyurea is an oral medicine that can help reduce 

sickle cell disease (SCD) complications.

People who take hydroxyurea must use it regularly as prescribed and receive 

consistent medical care. Ask your healthcare provider about the potential benefits 

and risks, and whether hydroxyurea is right for you.

Facts About Hydroxyurea

It has been a standard treatment for SCD 

for more than 30 years.

The Food and Drug Administration (FDA) 

approved hydroxyurea for severe SCD in 

1998 for adults and in 2017 for children.

It can reduce the likelihood of a 

pain crisis.

Hydroxyurea has been shown to reduce, by 

about half, the number of painful events a 

person with SCD may experience.

It has been shown to improve anemia and 

reduce the need for blood transfusions 

and hospital admissions.

One way to help reduce fatigue from anemia 

in people living with SCD is by increasing 

hemoglobin levels. This provides more oxygen to 

the body, giving the person with SCD increased 

energy. Studies have shown hydroxyurea is one 

of several drugs that does this.

It can reduce the number of 

episodes of acute chest syndrome, 

a medical emergency.

By increasing hemoglobin, hydroxyurea can 

potentially prevent the blockage of blood flow 

to the lungs.

Most experts recommend 

daily use of hydroxyurea 

for children and adults 

with sickle cell disease.

sicklecell.nhlbi.nih.gov
It may reduce the risk of stroke in children 

with SCD.

SCD reduces blood flow to the brain, which can 

cause a stroke, particularly in children.

It is not appropriate for anyone who 

is pregnant.

If you are thinking of becoming pregnant, 

talk to your doctor about when to stop 

taking hydroxyurea.

Hydroxyurea Use for Sickle Cell Disease

Questions to Ask Your 

Healthcare Provider

• How does hydroxyurea treat SCD?

• What are the possible short- and long-term 

side effects for me?

• How long would I need to take it?

• How many pills would I need to take 

every day?

• How often would I need to see my doctor 

when taking hydroxyurea?

• Are there other treatments I should consider?

SCD treatments, 

including hydroxyurea, 

may reduce symptoms 

and improve quality 

of life. Work with your 

healthcare provider to 

find what works best 

for you.

Learn more about available 

SCD treatments at 

sicklecell.nhlbi.nih.gov

NIH Publication No. 24-HL-8219 February 2024
Exhibit 32.1









CERTIFICATION PURSUANT TO


RULE 13A-14(B) OR RULE 15D-14(B)


OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO SECTION 906


OF THE SARBANES-OXLEY ACT OF 2002








In connection with the annual report on Form 10-K of Consolidation Services, Inc. (the “Company”) for the year ended December 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Johnny R. Thomas, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:





(a)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





(b)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.








Dated: March 31, 2010


CONSOLIDATION SERVICES, INC.








By:  /s/ Johnny R. Thomas


Johnny R. Thomas


Chief Executive Officer





A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Consolidation Services, Inc. and will be retained by Consolidation Services, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
United States Court of Appeals

Fifth Circuit

FILED

May 21, 2004

Charles R. Fulbruge III

Clerk

UNITED STATES COURT OF APPEALS

FIFTH CIRCUIT

_________________

No. 03-60951

(Summary Calendar)

_________________

BOBBY STEVENS; ET AL

Plaintiffs

BOBBY STEVENS; JOSEPHINE STEVENS

Plaintiffs - Appellants

versus

FORD MOTOR COMPANY; ET AL

Defendants

FORD MOTOR CO; JOHN DOES, whose names are unknown to plaintiffs

at this time, but will be substituted by amendment when ascertained; BILL

ETHRIDGE LINCOLN-MERCURY INC

Defendant - Appellees

GWENDOLYN HILL

Plaintiff - Appellant

versus

FORD MOTOR COMPANY; ET AL

Defendants

FORD MOTOR COMPANY; BILL ETHRIDGE LINCOLN-MERCURY

INC; JOHN DOES

Defendant - Appellees
*

 Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not be

published and is not precedent except under the limited circumstancesset forth in 5TH CIR.R. 47.5.4.

Appeal from the United States District Court

For the Southern District of Mississippi

USDC No. 4:03-CV-164-BN

Before BARKSDALE, EMILIO M. GARZA, and DENNIS, Circuit Judges.

PER CURIAM:*

PlaintiffsBobby and Josephine Stevens and Gwendolyn Hill bring this appealfromthe district

court’s denialoftheir Motion to Remand to state court their personal injury and propertydamage suit

against defendants Ford Motor Company, Bill Ethridge Lincoln-Mercury and unknown John Does.

“An order denying remand of a case removed to federal court is not a final order within the

meaning of 28 U.S.C. § 1291 and, standing by itself cannot be appealed unless certified by the district

court according to the provisions of 28 U.S.C. § 1292(b).” Poirrier v. Nicklos Drilling Co., 648 F2d

1063, 1064-65 (5th Cir. 1981); Aaron v. National Union Fire Ins. Co. of Pittsburgh, Pennsylvania,

876 F.2d 1157, 1160 (5th Cir. 1989); see Wright, Miller & Cooper, Federal Practice & Procedure

2d § 3914.11. When the refusal to remand is coupled with a final judgment, the appellate court has

jurisdiction to review the denial of the motion to remand. Aaron, 846 F.2d at 1160. 

The district court did not issue a final judgment in this case, no r did it certify its ruling for

interlocutory appeal. This appeal is thus DISMISSED.
CERTIFICATION PURSUANT TO
18 U.S.C. SS. 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002





In
connection with the Annual Report of Vertex Energy, Inc. (the "Company") on Form
10-K for the period ended December 31, 2009, as filed with the Securities and
Exchange Commission (the "Report"), I,
Christopher Stratton, Chief Financial Officer of the Company, certify, pursuant
to 18 U.S.C. ss. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that, to my knowledge:





(1) The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and





(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.








March
      30, 2010
            /s/
      Christopher StrattonChristopher
      StrattonChief
      Financial Officer
              (Principal
      Accounting Officer)
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[S. 37 Reported in Senate (RS)]

                                                       Calendar No. 221
109th CONGRESS
  1st Session
                                 S. 37

                          [Report No. 109-140]

 To extend the special postage stamp for breast cancer research for 2 
                                 years.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            January 24, 2005

Mrs. Feinstein (for herself, Mrs. Hutchison, Mr. Allen, Mr. Biden, Mr. 
  Lautenberg, Ms. Stabenow, Mr. Allard, Mr. Isakson, Mr. Cochran, Mr. 
     Durbin, Mr. Feingold, Mr. Johnson, Mr. Talent, Mr. Hatch, Ms. 
 Murkowski, Mr. Lieberman, Mrs. Murray, Mr. Salazar, Mr. Bunning, Mr. 
Thomas, Mrs. Boxer, Mrs. Clinton, Mr. Wyden, Mr. McCain, Mr. Voinovich, 
 Mr. Burr, Mr. Lugar, Mr. Specter, Mr. Corzine, Mr. Dorgan, Ms. Snowe, 
  Mr. Burns, Mrs. Dole, Mr. Domenici, Ms. Mikulski, Mr. Schumer, Mr. 
Lott, Mr. Santorum, Mr. Hagel, Mr. Vitter, Ms. Cantwell, Mr. Bayh, Mr. 
  Ensign, Mr. Jeffords, Ms. Landrieu, Mrs. Lincoln, Mr. Grassley, Mr. 
Chafee, Mr. Sarbanes, Mr. Baucus, Mr. Coleman, Mr. Warner, Mr. Stevens, 
   Mr. Coburn, Mr. Sessions, Mr. Nelson of Nebraska, Mr. Leahy, Mr. 
Martinez, Mr. Thune, Mr. Bond, Mr. Roberts, Mr. Alexander, Mr. Conrad, 
  Mr. Graham, Mr. Kyl, Mr. Cornyn, Mr. Sununu, Mr. Brownback, and Mr. 
Enzi) introduced the following bill; which was read twice and referred 
     to the Committee on Homeland Security and Governmental Affairs

                           September 26, 2005

               Reported by Ms. Collins, without amendment

_______________________________________________________________________

                                 A BILL

 
 To extend the special postage stamp for breast cancer research for 2 
                                 years.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. 2-YEAR EXTENSION OF POSTAGE STAMP FOR BREAST CANCER 
              RESEARCH.

    Section 414(h) of title 39, United States Code, is amended by 
striking ``2005'' and inserting ``2007''.
                                                       Calendar No. 221

109th CONGRESS

  1st Session

                                 S. 37

                          [Report No. 109-140]

_______________________________________________________________________

                                 A BILL

 To extend the special postage stamp for breast cancer research for 2 
                                 years.

_______________________________________________________________________

                           September 26, 2005

                       Reported without amendment
```
EXHIBIT 31.2

 

**CERTIFICATIONS**

I, John W. Swatek, certify that: 

 
| 1. | I have reviewed this quarterly report on Form 10-Q of Hanover Direct, Inc.; |
|----|-----------------------------------------------------------------------------|

 

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

a.     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

c.     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
|  

/s/ John W. Swatek

John W. Swatek

Senior Vice President,

Chief Financial Officer and Treasurer

 

  |
|---------------------------------------------------------------------------------------------------------------------------|

Date: February 21, 2006
Exhibit 32.1





CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER

PURSUANT TO 18 USC § 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002



In connection with the annual report of Premier Power Renewable
Energy, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2011 as filed with the Securities
and Exchange Commission (the “Report”), I, Dean R. Marks, Chief Executive Officer (Principal Executive Officer) of
the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States
Code, that to the best of my knowledge:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and
| | --- | -------------------------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the date and for the periods indicated.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------





| | Date: April 4, 2012                                                        
| | ---------------------------------------------------------------------------
| |                                                                            
| | /s/ Dean R. Marks                                                          
| | Dean R. Marks
        Chief Executive Officer (Principal Executive Officer)
EXHIBIT 32.2





CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002








In connection with the Quarterly Report of Arête Industries, Inc. (the "Company") on Form 10-Q for the period ending March 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, John Herzog, Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:





(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.







January 18, 2011
By:
/s/ John HerzogJohn Herzog, Interim Chief Financial Officer


A signed original of this written statement required by Section 906 has been provided to Arête Industries, Inc. and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
Exhibit 32.1




CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002




In connection with the Quarterly Report of NeoStem, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2011 filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robin Smith, M.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:




(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and




(2)
The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.




Dated:  May 16, 2011


/s/ Robin Smith, M.D.Robin Smith, M.D.Chief Executive Officer




The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.




A signed original of this written statement required by Section 906 has been provided to NeoStem, Inc. and will be retained by NeoStem, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
#### Iqbal Singh, Appellant, v City of New York Division of Housing Preservation and Development, Respondent.

Submitted November 30, 2009;

decided January 12, 2010

Reported below, 2009 NY Slip Op 76735(U).

Motion for reargument of motion for leave to appeal denied *[see*13 NY3d 826 (2009)].
## Contact Information

Bethesda MD20892

agyemangaf@mail.nih.gov 

January 2021

Back to Top
Exhibit 21

Subsidiaries of the registrant are as follows:



|                                                   |  |                                                          
|-------------------------------------------------- |  | ---------------------------------------------------------
|                                                   |  | State or OtherJurisdiction ofIncorporation orOrganization
|Boise Inc.                                         |  | Delaware                                                 
|BZ Intermediate Holdings LLC (100%)                |  | Delaware                                                 
|Boise Paper Holdings, L.L.C. (100%)                |  | Delaware                                                 
|Boise Finance Company (100%)                       |  | Delaware                                                 
|Boise Packaging & Newsprint, L.L.C. (100%)         |  | Delaware                                                 
|Louisiana Timber Procurement Company, L.L.C. (50%) |  | Delaware                                                 
|Boise White Paper, L.L.C. (100%)                   |  | Delaware                                                 
|Boise White Paper Sales Corp. (100%)               |  | Delaware                                                 
|Boise White Paper Holdings Corp. (100%)            |  | Delaware                                                 
|International Falls Power Company (100%)           |  | Delaware                                                 
|Minnesota, Dakota & Western Railway Company (100%) |  | Minnesota                                                
|Bemis Corporation (100%)                           |  | Delaware                                                 
|Boise Hong Kong Limited (100%)                     |  | Hong Kong                                                
|Boise Cascade Transportation Holdings Corp. (100%) |  | Delaware                                                 
|BCT, Inc. (100%)                                   |  | Delaware